Chengdu Olymvax Biopharmaceuticals Inc (688319.SH) resubmitted its application for an H-share listing on the Hong Kong Stock Exchange and published the application materials.
Olin Biosciences (688319.SH) announced that the company is in the process of applying for the overseas issuance of shares (H shares) and listing on the main board of the Hong Kong Stock Exchange. According to the timeline for this issuance and listing, the company resubmitted the application to the Hong Kong Stock Exchange on June 30, 2026, and the application materials were published on the Hong Kong Stock Exchange website on the same day. The application materials were prepared and published by the company in accordance with the requirements of the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange. They are draft versions, and the information contained in them may be updated and revised in a timely manner.
Chengdu Olymvax Biopharmaceuticals Inc (688319.SH) announced that the company is in the process of applying for the overseas issuance of shares (H shares) and listing on the main board of the Hong Kong Stock Exchange. According to the schedule for this issuance and listing, the company has resubmitted the application for issuance and listing on June 30, 2026 and published the application documents on the Hong Kong Stock Exchange website on the same day. The application documents were prepared and published by the company in accordance with the requirements of the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange, and are draft versions, with the information contained therein subject to timely updates and revisions.
Related Articles
CICC: Maintains REGINA MIRACLE (02199) at outperform rating with a target price of 2.38 Hong Kong dollars.
Guosen: The core competitiveness of scenic spots is shifting towards operational capability. In the short term, we should focus on the summer window from June to August.
A-share morning express: The ChiNext Index fell by 0.15%. Precious metals, insurance, innovative medicine, and other sectors are at the forefront of the decline.
CICC: Maintains REGINA MIRACLE (02199) at outperform rating with a target price of 2.38 Hong Kong dollars.
Guosen: The core competitiveness of scenic spots is shifting towards operational capability. In the short term, we should focus on the summer window from June to August.
A-share morning express: The ChiNext Index fell by 0.15%. Precious metals, insurance, innovative medicine, and other sectors are at the forefront of the decline.
RECOMMEND
